

No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening during the first and second waves in Paris

Maxime Wack, Hélène Péré, Nathalie Demory-Guinet, Najiby Kassis-Chikhani, Laurence Janot, Benoit Vedie, Laure Izquierdo, Laurent Bélec, David Veyer


▶ To cite this version:

Maxime Wack, Hélène Péré, Nathalie Demory-Guinet, Najiby Kassis-Chikhani, Laurence Janot, et al.. No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening during the first and second waves in Paris. Journal of Clinical Virology, 2021, 145, pp.104999. 10.1016/j.jcv.2021.104999. hal-03405624

HAL Id: hal-03405624 https://hal.sorbonne-universite.fr/hal-03405624v1


Submitted on 27 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



A. Weekly PCR results for health-care workers

B. Weekly serology results for health-care workers



2	SARS-CoV-2 reinfection among staff health-care workers:
3	Prospective hospital-wide screening
4	during the first and second waves in Paris
5	
6	Running title: No SARS-CoV-2 reinfection among HCWs
7	
8	Maxime Wack ^{1,2,*} , Hélène Péré ^{3,4,*} , Nathalie Demory Guinet ⁵ , Kassis Chikhani Najibi ⁶ , Laurence
9	Janot ⁵ , Benoit Vedie ⁷ , Laure Izquierdo ³ ,
10	Laurent Bélec ^{2,3,8} , David Veyer ^{3,4}
11	¹ Département d'Informatique Médicale, Biostatistiques et Santé Publique,
12	hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France;
13	² Faculté de Médecine, Université de Paris, Paris, 75005, France ;
14	³ Laboratoire de Virologie, Service de Microbiologie, hôpital européen Georges Pompidou,
15	Assistance Publique-Hôpitaux de Paris, Paris, 75015, France ;
16	⁴ Unité de Génomique Fonctionnelle des Tumeurs Solides,
17	Centre de Recherche des Cordeliers, INSERM, Université Paris, Paris, 75005, France.
18	⁵ Service de Médecine du Travail, hôpital européen Georges Pompidou,
19	Assistance Publique-Hôpitaux de Paris, Paris, 75015, France ;
20	⁶ Unité d'Hygiène Hospitalière, Service de Microbiologie, hôpital européen Georges Pompidou,
21	Assistance Publique-Hôpitaux de Paris, Paris, 75015, France ;
22	⁷ Laboratoire de Biochimie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de
23	Paris, Paris, 75015, France
24	⁸ INSERM U970, PARCC, hôpital européen Georges Pompidou, Faculté de Médecine,
25	Université de Paris, Paris, 75015, France ;
26	
27	
28	
29	Submitted as Full Length Article. Manuscript word count: 2492; Abstract word count: 200.
30	
31	
32	
33	
34	Corresponding author: David Veyer, Pharm D, PhD, Laboratoire de virologie, hôpital européen Georges
35	Pompidou, 20 rue Leblanc, 75015 Paris, France. Tel: (33)1 56 09 39 58; fax: (33)1 56 09 24 47; electronic
36	address: <u>david.veyer@aphp.fr</u>

38 Summary

39	<i>Objectives.</i> Risk of reinfection with SARS-CoV-2 among health-care workers (HCWs) is unknown.
40	We assessed the incidence rate of SARS-CoV-2 reinfection in the real-life setting of a longitudinal
41	observational cohort of HCWs from the Hôpital Européen Georges Pompidou, Assistance
42	Publique-Hôpitaux de Paris, France, during the first and second waves of COVID-19 epidemic.
43	Methods. From March to December 2020, HCWs were subjected to molecular and serology testing
44	of SARS-CoV-2. Reinfection was defined as a positive test result during the first wave, either by
45	serology or PCR, followed by a positive PCR during the second wave. Evolution of COVID-19
46	status of HWCs was assessed by a Sankey diagram.
47	Results. A total of 7765 tests (4579 PCR and 3186 serology) were carried out and 4168 HCWs had
48	at least one test result during the follow-up period with a positivity rate of 15.9%. No case of
49	reinfection during the second wave could be observed among 102 positive HCWs of the first wave,
50	nor among 175 HCWs found positive by PCR during the second wave who were negative during
51	the first wave.
52	Conclusions. SARS-CoV-2 reinfection was not observed among HCWs, suggesting a protective
53	immunity against reinfection that lasts at least 8 months post infection.
54	
55 56	Keywords: SARS-CoV-2; reinfection; health-care workers; vaccination; epidemiology
57	
58	
20	

59 Introduction

60

Health-care workers (HCWs) constitute a vulnerable population at high risk of SARS-CoV2 infection (1–3). During the first wave of COVID-19 epidemic in France, as of May 13, 2020,
more than 4,500 professionals were infected and 4 dead from COVID-19 in the *Assistance Publique-Hôpitaux de Paris* (AP-HP, which represents the largest group of university hospitals in
Europe, accounting for about 100 000 employees).

SARS-CoV-2 infection elicits both humoral and cellular, mucosal and systemic specific 66 immunity (4-6). A key question yet to be addressed is whether SARS-CoV-2 infection induces 67 68 long-lasting protective or sterilizing immunity. Our understanding of the immune correlates of protection for SARS-CoV-2 infection and their durability remains limited and depends mainly on 69 previous knowledge gained from SARS-CoV-1, the most closely related virus known to affect 70 71 humans (5,7). Furthermore, a number of cases of SARS-CoV-2 reinfection in humans have now been reported a few months after initial infection (8,9), including HCWs (10), challenging the 72 73 possibility of durable protective immunity. These findings may have implications for the need of continued protective measures and of further vaccination for persons previously infected with 74 75 SARS-CoV-2 (9).

76 In France, the SARS-CoV-2 epidemic officially began on January 24, 2020, with the first confirmed case of COVID-19 imported from China. Early April, the number of deaths from 77 coronavirus increased dramatically, with more than 10,000 people dying during that period of time. 78 The first wave of the COVID-19 epidemic was contained due to the first national lockdown that 79 80 extended from March 17, 2020 until May 10, 2020, the peak of the first wave being reached on the 1st of April 2020. During August 2020, COVID-19 cases began to rise again. On October 28, France 81 entered a second nationwide lockdown with progressive lifting starting from December 15. The 82 peak of the second epidemic wave was reached on the 20th of November 2020, but the epidemic has 83

since remained at a high plateau level. The duration period between the peaks of the first and
second waves was 7.8 months (234 days).

Our institution, the *Assistance Publique-Hôpitaux de Paris*, has largely promoted both molecular and serological testing for SARS-CoV-2 among healthcare staff, from the first wave of the COVID-19 epidemic (1). Molecular testing for SARS-CoV-2 of symptomatic hospital employees with COVID-19-related symptoms started on February 24, 2020. In addition, starting early April 2020, the *Assistance Publique-Hôpitaux de Paris* offered HCWs serological screening for SARS-CoV-2 to assess the prevalence of the infection during the first epidemic peak.

The intensity of COVID-19 epidemic in France in 2020 with a high risk of re-exposure to
SARS-CoV-2 infection for HCWs, as well as the availability of our centralized data-capture system
of all molecular and serological SARS-CoV-2 tests results, prompted us to assess the risk of SARSCoV-2 reinfections in a real-life setting in HCWs from our institution.

96

97 Materiel and method

98

99 Study design and participants recruitment.

The study was designed as an observational cohort with longitudinal analysis, focused on 100 molecular detection of SARS-CoV-2 RNA and immune response to SARSCoV-2 in volunteers 101 HCWs from the Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 102 tested during the first and second epidemic waves for suspected SARS-CoV-2 infection, contact 103 tracing and SARS-CoV-2 infection serological surveillance. Data included HCW ages, SARS-CoV-104 2 PCR and SARS-CoV-2 serology sampling dates and results. HCWs gender was not available. All 105 molecular and serological results were fully pseudonymized. July 15 2020 was considered as the 106 limit between the first and second epidemic waves. 107

During the first epidemic wave, the HCW participants were categorized into two groups 108 109 according to their molecular and serological results: positive if any SARS-CoV-2 PCR test and/or serology were positive, and negative if every SARS-CoV-2 PCR test and serology were negative. 110 111 During the second epidemic wave, the participants were categorized into two groups according to their molecular results, as positive if any SARS-CoV-2 PCR test was positive, and negative if every 112 SARS-CoV-2 PCR test were negative. In addition, HCW participants included during the first wave 113 114 but not tested during the second wave, and those included during the second wave but not tested during the first wave were categorized as participants with not available results (NA). Finally, 115 reinfection was defined as a positive result during the first wave, either by serology or PCR, 116 117 followed by a positive PCR during the second wave. If iterative PCR sampling occurred, reinfection was considered if a negative result was surrounded by 2 positive results. Furthermore, if 2 PCRs 118 119 were positive with more than 30 days between the sample dates without any negative results in 120 between, results were individually assessed by a virologist to decide if reinfection was confirmed or if remnant RNA from the original infection was still detected when the cycle threshold (Ct) value of 121 122 the PCR was over 33 (11). Positive serology during the first wave followed by positive PCR during the second wave was also considered a reinfection. 123

SARS-CoV-2 testing. Molecular detection of SARS-CoV-2 was carried out from flocked 124 nasopharyngeal swab samples using Allplex[™] 2019-nCoV Assay (Seegene, Seoul, Korea), a 125 multiplex real-time PCR assay that detects three coronavirus target genes (E gene, RdRP gene and 126 N gene) in a single tube, according to the manufacturer's instructions, as previously described (12). 127 Abbott SARS-CoV-2 IgG assay detecting IgG against SARS-CoV-2 nucleoprotein was used on 128 Architect analyzer (Abbott ArchitectTM i2000), according to manufacturer's instructions, as 129 previously described (13). Index value threshold for positivity was 1.4. Qualitative results were 130 used for analysis. 131

Statistical analysis. Categorical variables are presented as number (percentage and its [95% confidence interval]), and numeric variables as median or mean (SD or IQR). The number of test results was computed on a weekly basis. The evolution of the status for COVID-19 of HWCS between the two waves was assessed using a Sankey diagram, as described (14).

Ethics statement. Our observational study was carried out in accordance with the Declaration of Helsinki with no sampling addition to usual procedures. Swab and serum specimens were obtained only for standard diagnostic following medical prescriptions in the service of occupational medicine of our institution, and further eventual care. Under these conditions, the study was exempt from informed consent application, according to the French public health code (*Code de la Santé Publique*, article L 1121-1.1; <u>https://www.legifrance.gouv.fr/</u>). The dataset was completely anonymous and did not contain any identifiable personal health information.

143

- 144 **Results**
- 145

A total of 7765 tests, including PCR and serology, were collected from March 5, 2020 to
December 4, 2020 by the occupational medicine service at the *Hôpital Europèen Georges Pompidou*, Paris.

As depicted in the Figure 1, the weekly number of PCR tests evolved in accordance to the two waves of the epidemic of cases of SARS-CoV-2 infection in Paris. The number of serology tests per week evolved according to the curve resembling the first wave of the epidemic due to an institutional campaign for SARS-CoV-2 serology testing among HCWs between May and July.

Overall, 4579 PCR and 3186 serology tests were performed with positivity rates of 10.7% and 12.1%, respectively. A total of 4168 HCWs (median age, 34.3 years; IQR, 20.9 years) had at least one result, either PCR or serology, during the entire period with a positivity rate of 15.9%. There were 690 HCWs with at least one PCR result during the first wave *versus* 2340 during the second wave with a positivity rate of 21.3% and 14.1%, respectively. Conversely, 2737 HCWs had
a serology result during the first wave *versus* 417 during the second one, with a positivity rate of
9.8% and 27.8%, respectively (Table 1).

Among the 302 positive HCWs (either by serology or PCR) during the first wave, 102 were 160 tested by PCR at least once during the second wave (154 total PCRs), and all their PCR results were 161 162 negative (Figure 2). Furthermore, among the 330 PCR-positive HCWs during the second wave, 190 163 had a previous result from the first wave. Among those 190 that were tested in the first wave, there were 9 positive PCRs and 14 positive serology (15 total HCWs), and 170 negative serology and 45 164 negative PCRs (175 HCWs). All those 15 positive HCWs in the first wave were only positive in 165 166 serology in the second wave. Among the 2657 negative HCWs during the first wave, 175 had a positive PCR result (185 tests) and 965 (1859 tests) had a negative result during the second wave. 167 Overall, no case of reinfection during the second wave could be observed among the HCWs 168 169 population in our hospital. The observed reinfection incidence was thus 0% [95% CI: 0 - 3.55%].

170

171 **Discussion**

172

We herein assessed the incidence rate of SARS-CoV-2 reinfection in the real-life setting of a 173 longitudinal observational cohort of HCWs from one of the major university hospitals of the 174 Assistance Publique-Hôpitaux de Paris, France, during the first and second waves of COVID-19 175 epidemic in 2020. The longitudinal prevalence rates of SARS-CoV-2 infection among HCWs, 176 177 mostly symptomatic infections due to the design of the study, mimicked the curves of both waves of the COVID-19 epidemics in France with an overall rate of SARS-CoV-2 infection around 16%, 178 179 demonstrating possible occupational risk for SARS-CoV-2 infection in HCWs despite barrier protection measures within the community and hospital settings. Among the included SARS-CoV-2 180 infected HCWs tested for SARS-CoV-2 PCR swab and/or IgG serology in both the first and second 181

waves of the COVID-19 epidemic in Paris, no case of SARS-CoV-2 reinfection could be evidenced.
Thus, the risk of SARS-CoV-2 reinfection among HCWs appears negligible, despite the high level
of exposure to the virus during epidemic waves. Taken together, these observations demonstrate
that HCWs are at high risk of SARS-CoV-2 infection. SARS-CoV-2 reinfection was infrequent in
study HCWs, highly suggestive of a protective immunity against reinfection lasting at least 8
months following the primary infection.(1–3,15)

More than a seventh (15.9%) of HCWs showed at least one positive biological marker for SARS-CoV-2 during the nearly 8 months of study inclusion. The risk of SARS-CoV-2 infection in included HCWs strictly followed the waves of the COVID-19 epidemic in France, during which between 3% and 7% of French people will have been infected by SARS-CoV-2 (16). Thus, our findings suggest that HCWs are likely at supplementary risk for occupational SARS-CoV-2 infection, as previously reported in Paris and other settings (1–3,15).

194 The possibility of SARS-CoV-2 reinfection has raised important issues about the strength and durability of the immune response to primary infection, which are key factors in predicting the 195 196 course of the pandemic (8). We herein show SARS-CoV-2 reinfection was infrequent or absent among HCWs infected during the first wave of COVID-19 epidemic, despite their community and 197 occupational re-exposure during the second wave. Our observations are in agreement with the low 198 risk of SARS-CoV-2 reinfection generally reported (8,17), although the rates of reinfection with 199 SARS-CoV-2 can vary widely, depending on the criteria used, and also because it is difficult to 200 make the diagnosis with certainty, as previously pointed (18). By including the stringent criteria of 201 202 viral genomic data to distinguish reinfection from persistent viral carriage, only 16 documented 203 individual cases of reinfection confirmed by sequencing have been reported in the literature at the end of 2020 (8,19). Recently in Qatar, the risk of SARS-CoV-2 reinfection was estimated to be as 204 low as 1 case of reinfection per 5000 infected individuals (17). However, a 2,800 person study 205 found no symptomatic re-infections over a ~118 days window (20), and a 1,246 person study 206

observed no symptomatic re-infections over 6 months (21). Overall, SARS-CoV-2 re-infection is
considered a possible but rare event (8), in keeping with our observational study based on field
results from a well-documented hospital cohort.

210 SARS-CoV-2 infection consistently elicits neutralizing antibodies targeting the spike protein (in addition to other viral antigens), as well as CD8+ and CD4+ T cell responses (4-6). However, 211 212 the duration of effective immunity to SARS-CoV-2 remains unknown, and the issue of waning 213 immunity and reversion to a SARS-CoV-2 susceptible state over months to years is raised (22). Our observations of infrequent SARS-CoV-2 reinfection in hospital setting during the first and second 214 waves of COVID-19 epidemic in Paris are strongly suggestive of efficient and protective immunity 215 216 against reinfection that lasts at least 8 months post primary infection. These observations are in keeping with measurable immune memory in the three major branches of adaptive immunity (CD4+ 217 T cell, CD8+ T cell, and humoral immunity) in ~95% of subjects 5 to 8 months post symptom 218 219 onset, indicating that durable immunity against secondary COVID-19 disease is a possibility in most individuals (23). Obviously, further follow-up of SARS-CoV-2-infected HCWs over time may 220 221 allow characterization of potential effects of SARS-CoV-2-specific immunity waning.

The need to vaccine previously SARS-CoV-2-infected individuals remains the matter of 222 debate (9,24). It is possible that a fraction of the SARS-CoV-2-infected population with low 223 immune memory would become susceptible to re-infection relatively soon (23). Current 224 recommendations for COVID-19 vaccination from the World Health Organization (25) and the 225 Centers for Disease Control and Prevention (USA) (26) do not consider the fact of having been 226 infected with SARS-CoV-2. The National Health Service (UK) recommends to temporarily 227 postponing vaccination for 4 weeks after the onset of COVID symptoms (27). In France, the Haute 228 229 Autorité de Santé, Saint-Denis, has recommended that there is no need to systematically vaccinate people who have already developed a symptomatic form of COVID-19 (28). Our observations of 230 HCWs infected by SARS-CoV-2 harboring durable protection against reinfection for at least 8 231

months indicate that COVID-19 vaccination does not *a priori* constitute a priority in case a previous infection, especially if vaccine doses are limited. As vaccine candidates advance worldwide, serostatus for COVID-19 could be relevant in HCWS before vaccination. If it is determined that a single SARS-CoV-2 exposure induces long-lasting protective immunity, a positive serology test could indicate that an individual does not require vaccination or should not receive priority for vaccination (29). Finally, in case of vaccination in HCWS who have already been infected, the vaccination schedule could also possibly be simplified to a single dose.

Our study has some limitations. Except for HCWs that were recently exposed to positive 239 patients or colleagues (contact tracing), only HCWs volunteering for testing were included and 240 probably most of them had symptomatic infection. Furthermore, the possibility could be that 241 reinfections (if they occur) would have been asymptomatic or well tolerated and that they went 242 unnoticed without a biological diagnosis. Finally, HCWs in our institution were exposed to the 243 244 SARS-CoV-2 variants circulating in France until December 2020, and our study does not evaluate the possibility of reinfection by other variants, such as the new U.K. variant of SARS-CoV-2, which 245 246 various modeling exercises have estimated to be up to 70% more transmissible than the previously circulating form of the virus (30). 247

In conclusion, SARS-CoV-2 reinfection appears to be a rare phenomenon, if it exists, in HCWs despite their high level of exposure to the virus during epidemic peaks. This feature may suggest that effective immunity against SARS-CoV-2 infection develops after primary infection and lasts for at least 8 months, and that it is able to protect against reinfection. Finally, HCWs already infected with SARS-CoV-2 do not constitute a priority population for vaccination, especially as vaccine doses remain rationed.

255	Acknowledgments. The authors gratefully thank the department of clinical biochemistry, Hôpital
256	Européen Georges Pompidou, Paris, especially the technicians from the serological platform.

258	Author's contribution. HP, LB, DV designed the research. NDG, KCN, LJ provided clinical care
259	and biological specimens. LB, DV, LI, BV analyzed the samples. MW, DV performed statistical
260	analysis. HP, MW, LB, DV drafted the manuscript. All authors read and approved the final
261	manuscript.

268	1.	Contejean A, Leporrier J, Canouï E, Alby-Laurent F, Lafont E, Beaudeau L, et al. Comparing
269		Dynamics and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2
270		Transmissions Among Healthcare Workers of Adult and Pediatric Settings in Central Paris.
271		Clin Infect Dis. 2020 Jul 14;
272	2.	Hunter E, Price DA, Murphy E, van der Loeff IS, Baker KF, Lendrem D, et al. First
273		experience of COVID-19 screening of health-care workers in England. Vol. 395, The Lancet.
274		Lancet Publishing Group; 2020. p. e77–8.
275	3.	Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A
276		serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 May
277		12;26(7):1033–6.
278	4.	Canedo-Marroquín G, Saavedra F, Andrade CA, Berrios R V., Rodríguez-Guilarte L, Opazo
279		MC, et al. SARS-CoV-2: Immune Response Elicited by Infection and Development of
280		Vaccines and Treatments. Vol. 11, Frontiers in Immunology. Frontiers Media S.A.; 2020.
281	5.	Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological
282		Assays in SARS-CoV-2 Infections. Vol. 11, Frontiers in Immunology. Frontiers Media S.A.;
283		2020.
284	6.	Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding COVID-19. Vol. 54,
285		Immunity. Cell Press; 2021. p. 14–8.
286	7.	Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-
287		specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature.
288		2020 Aug 20;584(7821):457–62.
289	8.	Babiker A, Marvil C, Waggoner JJ, Collins M, Piantadosi A. The Importance and Challenges
290		of Identifying SARS-CoV-2 Reinfections. J Clin Microbiol. 2020 Dec 23;
291	9.	Cohen JI, Burbelo PD. Reinfection with SARS-CoV-2: Implications for Vaccines. Clin Infect

Dis. 2020 Dec 18;

- 293 10. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association
- Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients 294
- 295 With COVID-19. JAMA Intern Med [Internet]. 2020 Oct 20 [cited 2020 Oct 27]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33080002 296
- 11. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative Detection and Viral 297 Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020 Mar 28; 298
- 12. Péré H, Podglajen I, Wack M, Flamarion E, Mirault T, Goudot G, et al. Nasal Swab 299
- Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab 300
- 301 Shortage. Vol. 58, Journal of clinical microbiology. NLM (Medline); 2020.
- 13. Péré H, Védie B, Vernet R, Demory N, Kassis N, Mirault T, et al. Unexpected diagnosis of 302 COVID-19-associated disorders by SARS-CoV-2-specific serology. J Clin Virol. 2020 Nov 303 304 1;132.
- 14. Huang CW, Lu R, Iqbal U, Lin SH, Nguyen PA, Yang HC, et al. A richly interactive 305
- 306 exploratory data analysis and visualization tool using electronic medical records Clinical
- decision-making, knowledge support systems, and theory. BMC Med Inform Decis Mak. 307
- 2015 Nov 12;15(1). 308
- 309 15. Péré H, Wack M, Védie B, Demory Guinet N, Kassis Chikani N, Janot L, et al. Sequential
- SARS-CoV-2 IgG assays as confirmatory strategy to confirm equivocal results: Hospital-310
- wide antibody screening in 3,569 staff health care workers in Paris. J Clin Virol [Internet]. 311
- 2020 Nov 1 [cited 2020 Nov 28];132:104617. Available from: 312
- http://www.ncbi.nlm.nih.gov/pubmed/32927358 313
- Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the 314 16.
- burden of SARS-CoV-2 in France. Science (80-). 2020 Jul 10;369(6500):208-11. 315
- Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, et 17. 316

- al. Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting. Clin
 Infect Dis. 2020 Dec 14;
- Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW. Setting the criteria for
 SARS-CoV-2 reinfection six possible cases. Journal of Infection. W.B. Saunders Ltd;
 2020.
- 19. CDC. Investigative Criteria for Suspected Cases of SARS-CoV-2 Reinfection (ICR)
- Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Jan 29]. Available
 from: https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html
- 20. Wyllie D, Mulchandani R, Jones HE, Taylor-Phillips S, Brooks T, Charlett A, et al. SARS-
- 326 CoV-2 responsive T cell numbers are associated with protection from COVID-19: A
- 327 prospective cohort study in keyworkers. medRxiv. medRxiv; 2020. p. 2020.11.02.20222778.
- 21. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al.
- Antibodies to SARS-CoV-2 are associated with protection against reinfection. medRxiv.
- medRxiv; 2020. p. 2020.11.18.20234369.
- 331 22. Overbaugh J. Understanding protection from SARS-CoV-2 by studying reinfection. Nat
 332 Med. 2020 Nov 1;26(11):1680–1.
- 23. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to

334 SARS-CoV-2 assessed for up to 8 months after infection. Science (80-). 2021 Jan
335 6;eabf4063.

- Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: The status and perspectives in
 delivery points of view. Vol. 170, Advanced Drug Delivery Reviews. Elsevier B.V.; 2021. p.
 1–25.
- 339 25. Organization WH. WHO SAGE values framework for the allocation and prioritization of
- 340 COVID-19 vaccination, 14 September 2020 [Internet]. Geneva PP Geneva: World Health
- 341 Organization; Available from: https://apps.who.int/iris/handle/10665/334299

342	26.	Dooling K, McClung N, Chamberland M, Marin, M, Wallace M, Bell BP, et al. The
343		Advisory Committee on Immunization Practices' Interim Recommendation for Allocating
344		Initial Supplies of COVID-19 Vaccine — United States, 2020. MMWR Morb Mortal Wkly
345		Rep [Internet]. 2020 Dec 11 [cited 2021 Jan 29];69(49):1857–9. Available from:
346		http://www.cdc.gov/mmwr/volumes/69/wr/mm6949e1.htm?s_cid=mm6949e1_w
347	27.	COVID-19: the green book, chapter 14a - GOV.UK [Internet]. [cited 2021 Jan 29]. Available
348		from: https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a
349	28.	Haute Autorité de Santé - Stratégie de vaccination contre le Sars-Cov-2 - Recommandations
350		préliminaires sur la stratégie de priorisation des populations à vacciner [Internet]. [cited 2021
351		Jan 29]. Available from: https://www.has-sante.fr/jcms/p_3221338/fr/strategie-de-
352		vaccination-contre-le-sars-cov-2-recommandations-preliminaires-sur-la-strategie-de-
353		priorisation-des-populations-a-vacciner
354	29.	West R, Kobokovich A, Connell N, Gronvall GK. COVID-19 Antibody Tests: A Valuable
355		Public Health Tool with Limited Relevance to Individuals. Trends in Microbiology. Elsevier
356		Ltd; 2020.
357	30.	Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir
358		Med. 2021 Jan;

Table 1. SARS-CoV-2 RNA PCR and SARS-CoV-2-specific IgG serology results carried out
among HCWs in *Hôpital* Européen *Georges Pompidou*, Paris, France, during the first and second
waves of the COVID-19 epidemic in 2020.


	First wave	Second wave	Total
HCWs tested by PCR and/or serology [n]	2902	2506	4168
Age of tested HCWs [median (IQR); years]	37.1 (20.6)	32.1 (19.5)	34.3 (20.9)
SARS-CoV-2 PCR and serology [n]	3510	4255	7765
PCR [n]	759	3820	4579
[percent of positive (CI)]	19.5% (16.7 – 22.5)	8.9% (8.0 - 9.8)	10.7% (9.8 - 11.6)
Serology [n]	2751	435	3186
[percent of positive (CI)]	9.8% (8.7 - 10.9)	26.7% (22.6 - 31.1)	12.1 % (11.0 – 13.3)
HCWs tested positive by PCR and/or serology [n]	302	379	666
[percent (CI)]	10.4% (9.3 – 11.6)	15.1% (13.7 – 16.6)	15.9% (14.9 – 17.1))
HCWs tested by both PCR and serology [n]	525	251	1565
[percent of positivity by PCR or serology (CIs)]	41.5% (37.3 – 45.9)	47% (40.7 - 53.4)	31.3% (29.0 - 33.7)
[percent of positivity by both PCR and serology (CIs)]	21.5% (18.1 – 25.3)	26.7% (21.3 – 32.6)	11.6% (10.1 – 13.3)
HCWs with at least one PCR result [n]	690	2340	2719
[percent of positivity (CI)]	21.3% (18.3 – 24.5)	14.1% (12.7 – 15.6)	17.5% (16.1 – 18.9)
PCR per HCW [mean (SD)]	1.10 (0.30)	1.63 (0.90)	1.68 (1.02)
HCWs with at least one serology result [n]	2737	417	3014
[percent of positivity (CI)]	9.8% (8.7 - 10.9)	27.8% (23.6 - 32.4)	12.3% (11.2 – 13.4)
Serology per HCW [mean (SD)]	1.01 (0.08)	1.04 (0.23)	1.06 (0.25)

CI: Confidence interval; IQR: Interquartile range; HCW: Health-care worker; n: number; SD: Standard deviation;

369 Figures Legends

370

Figure 1. PCR and serology results during the first and the second wave of the COVID-19 pandemic. Weekly SARS-CoV-2 RNA PCR results (A.) and SARS-CoV-2-specific IgG serology results (B.) among staff HCWs in *Hôpital Européen Georges Pompidou*, Paris, France, during the first and second waves of the COVID-19 epidemic in 2020. The dashed vertical line indicates the separation between the first and second waves. The shaded areas correspond to the lockdown period decided by the French government. Positive and negative results are in red and blue, respectively.



380 HCWs in *Hôpital Européen Georges Pompidou*, Paris, France, between the first and the second

381	waves. Boxes on the left represent results either by PCR and/or serology during the first wave of the
382	SARS-CoV-2 epidemic, while those on the right represent results only by PCR during the second
383	wave. The different lanes show the status evolution with lane sizes proportional to the number of
384	HCWs. The blue lanes are for HCWs with no result during the second wave. The green lanes are for
385	HCWs with a negative result during the second wave. The red lanes are for HCWs with a positive
386	result during the second wave. NA: Results not available.